Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q1 2025
Aurinia Pharmaceuticals (AUPH) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Aurinia Pharmaceuticals (AUPH) reported revenue of $62.5M for the first quarter 2025 (Q1 2025), +24% from a year earlier and +4% from the quarter before. Operating margin was 35.0%, net earnings $23.3M (37.4% of revenue).
Aurinia Pharmaceuticals, Q1 2025: revenue $62.5M (+24% year over year), operating margin 35.0%, net earnings $23.3M, operating cash flow $1.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $62.5M | +4% | +24% |
| Operating profit | $21.8M | — | — |
| Net earnings | $23.3M | 16× | — |
| Operating cash flow | $1.3M | -96% | — |
What changed
Revenue was $62.5M in Q1 2025, up 24% year over year and up 4% from the previous quarter. Net product sales was the largest line at 96% of revenue. Net product sales added $11.9M year over year (up 25%), 98% of the total change.
Operating profit was $21.8M, a 35.0% margin (up 61.3 points year over year). Total costs fell 36% while revenue rose 24%. The fastest-growing cost line was Other operating costs (+133%). Net earnings were $23.3M. The effective tax rate was 4.1%.
Operating cash flow was $1.3M, 6% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization. Working capital and other items used $26.9M.
Questions
What was Aurinia Pharmaceuticals' revenue in the first quarter 2025?
Aurinia Pharmaceuticals (AUPH) reported revenue of $62.5M for the first quarter 2025 (Q1 2025), +24% from a year earlier and +4% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $21.8M (35.0% of revenue) and net earnings $23.3M.